Development of immunotherapies for autoimmune diseases and cancer Read more about our approach in Fierce Biotech KLRG1 – A Compelling Clinical Target in Immune Modulation Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer … Read More
Location: United States, Massachusetts, Newton
Employees: 11-50
Total raised: $197M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
| - | RA Capital... | racap.com |
| 25.08.2023 | New Leaf V... | nlvpartner... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.08.2023 | Series B | $155M | - |
| 07.01.2021 | Series A | $42M | - |
Mentions in press and media 8
| Date | Title | Description | Source |
| 29.09.2023 | Eurofarma anuncia un fondo de 100M$ para invertir en startup... | Eurofarma, compañía farmacéutica brasileña con presencia en América Latina y EE. UU., ha anunciado e... | elreferent... |
| 18.08.2023 | Abcuro Raises $155M in Series B Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatme... | finsmes.co... |
| 17.08.2023 | Sanofi-backed Abcuro loads up with $155M series B to push KL... | Abcuro will draw on an oversubscribed series B round to continue the journey of its anti-KLRG1 candi... | fiercebiot... |
| 07.10.2022 | Sanofi's BD chief heads to Owkin as CBO; Roche relies on it... | Alban de La Sablière Up until recently, Alban de La Sablière was Sanofi’s chief dealmaker, r... | endpts.com... |
| 08.01.2021 | Daily funding roundup - January 8th, 2021 | SilviaTerra raised $4.4M; Hipcamp landed $57M; DiCE Molecules secured $80M; Affinivax picks up $226M... | vator.tv/n... |
| 07.01.2021 | Sanofi-backed Abcuro bags $42M to trial KLRG1 immunotherapy | Abcuro has raised $42 million in a Sanofi Ventures co-led series A to advance anti-KLRG1 treatments ... | fiercebiot... |
| 07.01.2021 | Abcuro Raises $42 Million in Series A-1 | NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing ther... | citybizlis... |
| - | Abcuro | “Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.” | fastfounde... |